Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer.

Int J Gynecol Pathol

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Duke Cancer Institute (B.A.D., A.A.S., A.B., P.S.L., L.J.H.) Departments of Obstetrics and Gynecology, Division of Gynecologic Oncology (J.E., Z.H.) Pathology (S.A., A.H.S.H.) Biostatistics (X.L.), Duke University Medical Center, Durham, North Carolina Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Virginia Tech Carilion School of Medicine, Roanoke, Virgina (F.A.V.).

Published: May 2018

To determine whether the processing of additional adipose tissue collected during lymph node (LN) dissection results in the identification of additional LNs during endometrial cancer (EC) staging and to determine if the division of LNs into nodal basin-specific specimens has an effect on the number of LNs identified during EC staging. A prospective randomized controlled trial was performed on women with high-grade EC undergoing surgical staging. Subjects were randomized to collection of LNs into nodal basin-specific containers on the randomized side versus simple labeling on the nonrandomized side. The total number of LNs and total number of LNs with metastases on the randomized versus the nonrandomized side were compared. The remaining adipose tissue from each LN specimen was submitted for histologic examination. We analyzed the number of LNs with and without metastases identified from additional adipose tissue. Of 120 consented subjects, 56 had sufficient data for analysis. The additional adipose tissue contained 7.5 additional LNs per patient on average (range: 0-26). In 2/54 total cases (3.7%) and 2/5 cases with nodal metastases (40%), the additional adipose contained LNs with metastases. In both cases, metastases were also detected in grossly identified LN candidates. The mean number of LNs identified was not significantly different based on method of collection (P=0.22). The mean number of LNs containing metastases per side was not significantly different (P=0.58). Processing of adipose tissue does increase the total number of LNs identified, however, it does not influence EC stage. No difference in LN counts was noted with basin-specific collection.

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000418DOI Listing

Publication Analysis

Top Keywords

number lns
28
adipose tissue
20
additional adipose
16
lns metastases
16
lns
12
lns identified
12
total number
12
lymph node
8
endometrial cancer
8
additional lns
8

Similar Publications

Background: Early and delayed puberty are both associated with adverse health and psychosocial outcomes.

Objectives: We assessed the impact of provision of small-quantity lipid-based nutrient supplement (SQ-LNS) to mothers during pregnancy and 6 mo postpartum and to their children aged 6-18 mo, on pubertal status.

Methods: This study was a follow-up to a partially double-blind randomized controlled trial.

View Article and Find Full Text PDF

Background: The use of lymph node (LN) tracers can help obtain a complete dissection of the LNs and increase the detection rate of metastatic LNs. Carbon nanoparticle suspension injection (CNSI) has become increasingly used in radical gastrectomy procedures. This study is designed to evaluate the quality of LN dissection in gastric cancer patients with laparoscopic distal gastrectomy under the guidance of CNSI lymphography.

View Article and Find Full Text PDF

[F]FDG PET/CT for predicting neoadjuvant PD-L1 blockade monotherapy treatment response in patients with locally advanced esophageal squamous cell carcinoma: a preliminary study.

Eur J Nucl Med Mol Imaging

January 2025

Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180 in Fenglin Road, Shanghai, 200032, P.R. China.

Purpose: To investigate the predictive value of 2-[18F]-fluoro-2-deoxy-D-glucose ([F]FDG) PET/CT for evaluating primary tumor (PT) and lymph node (LN) responses after neoadjuvant programmed death-ligand 1 (PD-L1) blockade monotherapy in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC).

Methods: In the single-arm phase 1b NATION-1907 trial (NCT04215471), 23 patients with LA-ESCC received two cycles of neoadjuvant PD-L1 blockade Adebrelimab followed by surgery. Among these, 18 patients underwent [F]FDG PET/CT scans both before immunotherapy and prior to surgery.

View Article and Find Full Text PDF
Article Synopsis
  • Endoscopic-assisted breast surgery (EABS) offers better cosmetic results for breast cancer patients, but traditional axillary lymph node dissection (ALND) requires larger incisions and more retraction.
  • The proposed single-port three-dimensional endoscopic-assisted ALND (S-P 3D E-ALND) uses a minimally invasive technique with high success rates and improved visualization, analyzed from a study of 11 patients.
  • Preliminary results show 100% success without open surgery conversion, short operative times, minimal blood loss, and no significant complications over a median follow-up of 7 months, suggesting that S-P 3D E-ALND is a viable alternative for ALND.
View Article and Find Full Text PDF

Does lymph node dissection improve the prognosis of patients with colorectal cancer?

World J Gastrointest Surg

December 2024

Graduate School of Qinghai University, The Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China.

The number of lymph nodes (LNs) dissected during surgery has become an interesting topic. Simple intuition always leads us to believe that dissecting more LNs will result in more accurate pathological staging and assurance of surgical quality. However, when the number of LNs dissected reaches a certain threshold, the patient's prognosis does not continue to improve as the number of dissected nodes increases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!